Summary
Eltoprazine. HCl belongs to a new class of psychotropic drug, the serenics. The dose-proportionality and pharmacokinetics of eltoprazine HCl has been investigated after single oral doses of 5, 10, 20 mg (18 subjects) and 30 mg (12 subjects) in a partly randomized, cross-over design.
Eltoprazine was well tolerated and there were no relevant changes in safety parameters. All subjects showed irregular plasma-concentration-time profiles, some subjects demonstrating secondary peaks. The mean half-life was calculated to be about 6.5 h. The renal excretion of eltoprazine was characterized by net tubular secretion. AUC, peak plasma concentrations and the amount excreted unchanged in the urine were linearly related to the dose. Renal clearance and t1/2 were independent of dose.
Thus, eltoprazine HCl was well tolerated orally and exhibited a linear pharmacokinetic profile.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Olivier B, Van Dalen D, Hartog J (1986) A new class of psychoactive drugs: serenics. Drugs Future 11: 473–494
Olivier B, Mos J (1986) Serenics and aggression. Stress Med 2: 197–209
Olivier B, Mos J, Van der Heyden H, Schipper J, Tulp M, Berkelmans B, Bevan P (1987) Serotonergic modulation of agonistic behaviour. In: Olivier B, Mos J, Brain PF (eds) Ethopharmacology of agonistic behaviour in animals and humans. Nijhoff, Dordrecht, pp 162–186
Olivier B, Mos J, Tulp M, Schipper J, Den Daas S, Van Oortmerssen G (1990) Serotonergic involvement in aggressive behaviour in animals. In: Van Praag HM, Plutchik R, Apter A (eds) Violence and suicidality: perspectives in clinical and psychobiological research. Brunner/Mazel, New York, pp 79–137
Bevan P, Olivier B, Schipper J, Mos J (1990) Serotonergic function and aggression in animals. In: Serotonin: actions, receptors, pathophysiology. Mylecharane MA, Angus JA, de la Lande IS, Humphry PPA (eds) Macmillan, England, pp 101–108
Schipper J, Tulp M, Sijbesma H (1990) Neurochemical profile of eltoprazine. Drug Metabol Drug Interact 8: 85–114
Olivier B, Mos J, Rasmussen D (1990) Behavioural pharmacology of the serenic, eltoprazine. Drug Metabol Drug Interact 8: 31–83
Van Harten J, Mathlener IS, Raghoebar M (1990) Pharmacokinetics of eltoprazine in healthy subjects. Drug Metabol Drug Interact 8: 149–158
Raghoebar M, Mak M, Cournot A, Pistorius MCM, van Harten J, Roseboom H (1990) Pharmacokinetics of eltoprazine hydrochloride in healthy male subjects after single dose oral and intravenous administration. Br J Clin Pharmacol 30: 879–883
Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New York
Sheiner L, Beal S (1980) Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten Model: Routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8: 553–571
Gomeni R (1984) Pharm. An interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 14: 24–34
Grahnén A, von Bahr C, Lindström B, Rosén A (1979) Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol 16: 335–340
Grahnén A (1984) Cimetidine bioavailability and variable renal clearance. Eur J Clin Pharmacol 27: 623–624
Grahnén A (1985) The impact of time dependent phenomena on bioequivalence studies. In: Breimer DD, Speiser P (eds) Topics in pharmaceutical sciences 1985, Elsevier, Amsterdam, pp 179–190
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Vries, M.H., de Koning, P., Floot, H.L. et al. Dose-proportionality of eltoprazine. Eur J Clin Pharmacol 41, 485–488 (1991). https://doi.org/10.1007/BF00626375
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00626375